Skip to content


  • Poster presentation
  • Open Access

Collaboration in long term follow-up of juvenile idiopathic arthritis

  • 1,
  • 1,
  • 1,
  • 1,
  • 1,
  • 1 and
  • 1
Pediatric Rheumatology20086 (Suppl 1) :P75

  • Published:


  • Methotrexate
  • Etanercept
  • Juvenile Idiopathic Arthritis
  • Functional Impairment
  • Amyloidosis


Since many patients with juvenile idiopathic arthritis (JIA) are lost to follow-up in adulthood, we have started a transition clinic with further follow-up, in order to assess the outcome of adults who had JIA during childhood and who still have active inflammatory arthritis.


18 patients (13 female, 5 male) seen since the year 1998 and regularly followed at the rheumatology clinic are included.


The mean age is 29 years; the mean duration of disease is 22 years. 8 were polyarticular in onset (all rheumatoid factor negative): joint erosions are noted in 4, hip replacement in 2, amyloidosis in 1 (renal graft); 5 are on methotrexate, 3 on etanercept; functional impairment is evident in 1/8, seven are employed.

Of the 10 who had systemic-onset disease, erosions are present in 4, hip replacement in 2, amyloidosis in 1; 3 are treated with methotrexate, 1 leflunomide, 3 etanercept; disability in 3, 4 are students and 3 are employees.

Globally 33% of patients need anti TNF, while 83% work.


Studies of the outcome of JIA at adult age with persistent inflammatory symptoms are few. This cohort emphasizes the need of prolonged treatment with methotrexate and anti TNF in cases of active disease. However, overall prognosis looks relatively good in term of work ability.

Authors’ Affiliations

Hospices Civils de Lyon, Lyon, France


© Larbre et al; licensee BioMed Central Ltd. 2008

This article is published under license to BioMed Central Ltd.